Biotech Values

[genisi]

There are several ways to break such exclusivity - if the new drug is better or safer or if there is a shortage and patients cannot get treatment, are few ways. Cerezyme shortage is not entirely over plus Shire has reached its capacity limit, so seems to me as a valid claim. I most certainly agree on the 2nd claim being a stronger one. Just hope PLX people read this